Endpoint selection for noninferiority percutaneous coronary intervention trials: a methodological description.
Matthias W WaliszewskiMark RosenbergHarald RittgerViktor BreulFlorian KrackhardtPublished in: Therapeutic advances in cardiovascular disease (2020)
Expanded composite clinical endpoints (MACE complemented by ST and bleeding rates and intrapatient randomization for selected surrogate endpoints) may be suitable tools to meet future needs in device approval, recertification and reimbursement.
Keyphrases
- percutaneous coronary intervention
- atrial fibrillation
- st segment elevation myocardial infarction
- acute coronary syndrome
- acute myocardial infarction
- coronary artery disease
- st elevation myocardial infarction
- current status
- antiplatelet therapy
- coronary artery bypass grafting
- coronary artery bypass
- heart failure
- drug administration